ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Ahmad Tarhini, Shelby L. Corman, Sumati Rao, Kim Margolin, Xiang Ji, Sonam Mehta, Marc F. Botteman
Background: To describe healthcare costs, excluding ipilimumab drug costs, in patients with advanced melanoma receiving ipilimumab in the US community practice setting. Methods: This was a retrospective chart review of unresectable stage III/IV melanoma patie…
Beate Senn, Andrea Kobleder, Silvia Raphaelis, Michael D. Mueller, Beatrice Kammermann, Kathryn White, Manuela Eicher
Purpose: Women who are surgically treated for vulvar cancer often have complications leading to substantial patient morbidity. Post-surgical complications could be minimized by the identification of pre-surgical risks for complications and by planned post-sur…
Mais Almumen
Background: Several molecular markers have been detected that are important in clinical aspect of malignancies especially in breast cancer. More recently, the expression of vascular endothelial growth factor (VEGF), the most potent endothelial cell mitogen an…
Bangaly Traore, Abdoulaye Toure, Telly Sy, Mamadou Moustapha Dieng, Mamoudou Condé, Ahmadou Deme, Namory Keita
Background: We aim to review different factors associated with the relapse and the mortality in breast cancer patients in restricted-resource settings over a five-year period. Method: A retrospective cohort study including 133 women underwent breast cancer su…
Hrishikesh Sil, Amitava Chatterjee
The present study aimed to detect comparative expression of integrin α V β 3 and its involvement in expression and activation of matrix metalloproteinase-2 (MMP-2) in 25 malignant human breast tumor and adjacent normal breast tissues from different clinical T…
Mouna Zerradi, François Houle, Jacques Huot
Background: Tropomyosin 1 alpha chain (Tm1) is an actin-binding protein that regulates the endothelial cell response to oxidative stress following its phosphorylation at Serine 283 (S283). Tm1 is also a major tumor suppressor in breast cancer. In the present…
Sally A. Litherland, Louis Barr, Robert Reynolds, Elizabeth Griffith, Ryan Sause, Tiffany Encarnacion, Alvin J. O. Almodovar, Xiang Zhu, Stephanie Dickstein, Yai-Ping Shao, Na’im Fanaian, David A. Decker
Recent clinical trials with histone deacetylase inhibitors (HDACi) have shown increased progression free survival by re-sensitizing resistant estrogen receptor positive (ER+) breast cancer cells to hormone suppressive therapies (HT). However, these trials lac…
Alvin J. O. Almodovar, Xiang Zhu, Sally A. Litherland, David A. Decker, 1 1
Promestriene (3-propyl ethyl, 17B-methyl estradiol) is a synthetic estrogen analogue with reported minimal systemic absorption which has been suggested for topical treatment of vaginal atrophy. Promestriene’s ability to stimulate proliferation and estrogen re…
Shintaro Ishiyama, Yoshio Imahori, Jun Itami, Hanna Koivunoro
Purpose: In defining the biological effects of the 10 B( n , α ) 7 Li neutron capture reaction, we have proposed a deterministic parsing model ( ISHIYAMA-IMAHORI model) to determine the Compound Biological Effectiveness ( CBE ) factor in Borono-Phenyl-Alanine…
Ahmed A. Refae, Ahmed Ezzat, Dina Ahmed Salem, Mervat Mahrous
Purpose: Radiotherapy with concurrent temozolomide (TMZ), followed by 6 cycles of adjuvant TMZ, is the standard of care for newly diagnosed Glioblastoma Mulltiforme (GBM). However tumor progression is the role with median survival of almost 14 months. With la…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).